Leland Gershell
Stock Analyst at Oppenheimer
(4.49)
# 287
Out of 4,984 analysts
141
Total ratings
48.85%
Success rate
26.94%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $15.06 | +431.21% | 1 | Sep 3, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $8 | $7.67 | +4.30% | 3 | Aug 8, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $28 → $32 | $18.62 | +71.86% | 6 | Aug 7, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $50.98 | +115.77% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $51.18 | +19.19% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $451.73 | +8.47% | 8 | Aug 4, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $20 | $5.36 | +273.13% | 1 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $76 → $110 | $96.10 | +14.46% | 2 | Jul 10, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $6.08 | +261.84% | 5 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $215 → $224 | $199.59 | +12.23% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $18.10 | +71.27% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $2.12 | +372.81% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $734.35 | -3.59% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.61 | +521.12% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $7.98 | +150.63% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $54.37 | +80.25% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $38.88 | +33.74% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $3.42 | +1,361.99% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.20 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $15.11 | +250.76% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $6.52 | +360.12% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.58 | +365.12% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $3.96 | +126,322.25% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.03 | +725.08% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $34.20 | +113.45% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $3.20 | +525.00% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $20.02 | +44.86% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $11.33 | +208.91% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.72 | +1,284.47% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.15 | +1,639.13% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.94 | +570.10% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.04 | +3,847.37% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.17 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $18.38 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.91 | +2,524.67% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.60 | - | 5 | Mar 31, 2020 |
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $15.06
Upside: +431.21%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $7.67
Upside: +4.30%
Viridian Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $18.62
Upside: +71.86%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $50.98
Upside: +115.77%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $51.18
Upside: +19.19%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $451.73
Upside: +8.47%
Lexeo Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $5.36
Upside: +273.13%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $96.10
Upside: +14.46%
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $6.08
Upside: +261.84%
Ascendis Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $199.59
Upside: +12.23%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $18.10
Upside: +71.27%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $2.12
Upside: +372.81%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $734.35
Upside: -3.59%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.61
Upside: +521.12%
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $7.98
Upside: +150.63%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $54.37
Upside: +80.25%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $38.88
Upside: +33.74%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $3.42
Upside: +1,361.99%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.20
Upside: -
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $15.11
Upside: +250.76%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $6.52
Upside: +360.12%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.58
Upside: +365.12%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $3.96
Upside: +126,322.25%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.03
Upside: +725.08%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $34.20
Upside: +113.45%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $3.20
Upside: +525.00%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $20.02
Upside: +44.86%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $11.33
Upside: +208.91%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.72
Upside: +1,284.47%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.15
Upside: +1,639.13%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.94
Upside: +570.10%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.04
Upside: +3,847.37%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.17
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $18.38
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.91
Upside: +2,524.67%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.60
Upside: -